← SynDRA
REGORAFENIB
SynDRA canonical compound SYN0028680 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | TEK |
|---|
| Mechanism of action | RET tyrosine kinase inhibitor |
|---|
| Indication | colorectal cancer | gastrointestinal stromal tumors (GIST) |
|---|
| Disease area | oncology |
|---|
All known targets
- KDR
- KIT
- BRAF
- RET
- DDR2
- ABL1
- MAPK11
- FLT1
- FGFR1
- FLT4
- PDGFRB
- RAF1
Mechanisms of action (all sources)
- KIT INHIBITOR
- RAF inhibitor
- FGFR inhibitor
- PDGFR inhibitor
- VEGFR inhibitor
- RET tyrosine kinase inhibitor
- ABL1 INHIBITOR
- Tyrosine-protein kinase ABL inhibitor
- RAF1 INHIBITOR
- Serine/threonine-protein kinase RAF inhibitor
- Stem cell growth factor receptor inhibitor
- FGFR1 INHIBITOR
Drug classes
- Protein Kinase Inhibitors
- Kinase Inhibitor
- Cytochrome P450 2C9 Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- regorafenib monohydrate
- Stivarga
- regorafenib hydrate
- anhydrous regorafenib
- BAY 73-4506
- Regorafenib hydrate
- Regorafenib anhydrous
- Regorafenib monohydrate
- BAY-73-4506
- BAY-73-4506 MONOHYDRATE
- BAY-734506
- BAY-734506 MONOHYDRATE
- Regorafenibum
- 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide
- BAY73-4506
- Regorafenib (BAY 73-4506)
- UNII-24T2A1DOYB
- 4-[4-({[4-Chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
- 24T2A1DOYB
- CHEMBL1946170
- CHEBI:68647
- Stivarga (TN)
- BAY73-4506 hydrochloride
- Regorafenib [USAN:INN]
- Regorafenib-13C-d3
- 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
- REGORAFENIB ANHYDROUS
- BAY 734506
- Regorafenib (BAY73-4506,Fluoro-Sorafenib)
- 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide
- Regorafenib [INN]
- Fluoro-Sorafenib
- 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl}amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide
- REGORAFENIB [MI]
- Regorafenib (USAN/INN)
- REGORAFENIB [VANDF]
- REGORAFENIB [WHO-DD]
- MLS006010303
Reported adverse events
- Alopecia
- Dysphonia
- Headache
- Hypertension
- Infection
- Lymphopenia
- Muscle spasms
- Nausea
- Neutropenia
- Pain
- Proteinuria
- Rash
Look up REGORAFENIB in the interactive SynDRA portal →